Details for Patent: 9,216,996

« Back to Dashboard

Which drugs does patent 9,216,996 protect, and when does it expire?

Patent 9,216,996 protects BIKTARVY, BIXLENVO, and BIXLENVO SUNLENCA STARTER PACK (COPACKAGED), and is included in three NDAs.

This patent has one hundred and thirty-eight patent family members in forty countries.

Summary for Patent: 9,216,996

Title:	Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections
Abstract:	Compounds for use in the treatment of human immunodeficiency virus (HIV) infection are disclosed. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, X, W, Y1, Y2, Z1, and Z4are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
Inventor(s):	Haolun Jin, Scott E. Lazerwith, Hyung-Jung Pyun
Assignee:	Gilead Sciences Inc
Application Number:	US14/133,858
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,216,996
Patent Claim Types: see list of patent claims	Composition;

Drugs Protected by US Patent 9,216,996

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-002	Oct 7, 2021		RX	Yes	No			Y	Y
Gilead Sciences Inc	BIKTARVY	bictegravir sodium; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	210251-001	Feb 7, 2018		RX	Yes	Yes			Y	Y
Gilead Sciences Inc	BIXLENVO	bictegravir sodium; lenacapavir sodium	TABLET;ORAL	221104-001	Aug 27, 2026		RX	Yes	Yes			Y	Y
Gilead Sciences Inc	BIXLENVO SUNLENCA STARTER PACK (COPACKAGED)	bictegravir sodium, lenacapavir sodium; lenacapavir sodium	TABLET;ORAL	221443-001	Aug 27, 2026		RX	Yes	Yes			Y	Y

International Family Members for US Patent 9,216,996

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2822954		300947	Netherlands
European Patent Office	2822954		122018000094	Germany
European Patent Office	2822954		LUC00083	Luxembourg
European Patent Office	2822954		CA 2018 00029	Denmark
European Patent Office	2822954		PA2018511	Lithuania
European Patent Office	2822954		33/2018	Austria
European Patent Office	2822954		2018C/031	Belgium